Phosphoinositide 3-kinase delta (PI3Kδ)
Assets acting on this target.
- Class
- PI3Kδ inhibitor
- Notes
- mechanism wave 2026-08-24 (DeepSeek draft; registry text of NCT02972905 names the target); source: https://clinicaltrials.gov/study/NCT02972905
Assets acting on this target.
1 of 1 assets (1 discontinued)
| Drug | Owner | Mechanism | Indication | Reached | Why it stopped | Source |
|---|---|---|---|---|---|---|
| nemiralisib | GlaxoSmithKline | Phosphoinositide 3-kinase delta (PI3Kδ) | Asthma | Ph 2 | GSK2269557 (nemiralisib), an inhaled PI3K-delta inhibitor, was explored for asthma alongside COPD and bronchiectasis, but current GSK clinical activity for this molecule is focused on acute COPD exacerbations, with the most recent published trial data from 2021. No dedicated asthma trial or pipeline disclosure shows current company-directed asthma development. | source ↗ |